SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lee SG, Park KM, Hwang S, Lee YJ, Kim KH, Ahn CS, et al. Adult-to-adult living donor liver transplantation at the Asan Medical Center, Korea. Asian J Surg 2002;25:277-284.
  • 2
    Laryea M, Watt KD, Molinari M, Walsh MJ, McAlister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007;13:1109-1114.
  • 3
    Colle I, Van Vlierberghe H, Troisi R, De Hemptinne B. Transplanted liver: consequences of denervation for liver functions. Anat Rec A Discov Mol Cell Evol Biol 2004;280:924-931.
  • 4
    John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002;8:708-713.
  • 5
    Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation 2002;74:1007-1012.
  • 6
    Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: long-term follow up. Transplantation 2006;82:1625-1628.
  • 7
    Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010;89:1134-1140.
  • 8
    Oufroukhi L, Kamar N, Muscari F, Lavayssière L, Guitard J, Ribes D, et al. Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation. Transplantation 2008;85:1436-1442.
  • 9
    Kang ES, Kim MS, Kim CH, Nam CM, Han SJ, Hur KY, et al. Association of common type 2 diabetes risk gene variants and posttransplantation diabetes mellitus in renal allograft recipients in Korea. Transplantation 2009;88:693-698.
  • 10
    Lee HC. Post-renal transplant diabetes mellitus in Korean subjects: superimposition of transplant-related immunosuppressant factors on genetic and type 2 diabetic risk factors. Diabetes Metab J 2012;36:199-206.
  • 11
    Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004;10:349-355.
  • 12
    Mirabella S, Brunati A, Ricchiuti A, Pierini A, Franchello A, Salizzoni M. New-onset diabetes after liver transplantation. Transplant Proc 2005;37:2636-2637.
  • 13
    Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C, et al.; for Diapason Study Group. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007;13:136-144.
  • 14
    Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, et al. Risk factors associated with the onset and progression of posttransplantation diabetes in renal allograft recipients. Diabetes Care 2007;30:609-615.
  • 15
    Sarno G, Mehta RJ, Guardado-Mendoza R, Jimenez-Ceja LM, De Rosa P, Muscogiuri G. New-onset diabetes mellitus: predictive factors and impact on the outcome of patients undergoing liver transplantation. Curr Diabetes Rev 2013;9:78-85.
  • 16
    Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. Endocrinol Metab Clin North Am 2007;36:873-890.
  • 17
    Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008;14:1648-1654.
  • 18
    Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001;7(suppl 1):S13-S21.
  • 19
    Gotto AM Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 2012;110(suppl):3A-14A.
  • 20
    Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
  • 21
    Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983;6:23-25.
  • 22
    Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernández D, et al.; for International Expert Panel. New-onset diabetes after transplantation: 2003 international consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003;75(suppl):SS3-SS24.
  • 23
    Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-2564.
  • 24
    Goldstein MR, Mascitelli L. Do statins cause diabetes? Curr Diab Rep 2013;13:381-390.
  • 25
    Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066-1072.
  • 26
    Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010;10:1420-1427.
  • 27
    Parekh J, Corley DA, Feng S. Diabetes, hypertension and hyperlipidemia: prevalence over time and impact on long-term survival after liver transplantation. Am J Transplant 2012;12:2181-2187.
  • 28
    Kang ES, Kim MS, Kim YS, Hur KY, Han SJ, Nam CM, et al. A variant of the transcription factor 7-like 2 (TCF7L2) gene and the risk of posttransplantation diabetes mellitus in renal allograft recipients. Diabetes Care 2008;31:63-68.
  • 29
    Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW, et al. A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 2008;57:1043-1047.
  • 30
    Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005;67:2415-2421.
  • 31
    Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg 1998;4:285-296.
  • 32
    Xia F, Xie L, Mihic A, Gao X, Chen Y, Gaisano HY, Tsushima RG. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic β-cells. Endocrinology 2008;149:5136-5145.
  • 33
    Mulder H, Ling C. Mitochondrial dysfunction in pancreatic β-cells in type 2 diabetes. Mol Cell Endocrinol 2009;297:34-40.
  • 34
    Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, Lee NS, et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012;52:198-207.
  • 35
    Kusminski CM, Scherer PE. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab 2012;23:435-443.
  • 36
    Khamseh ME, Malek M, Aghili R, Emami Z. Sarcopenia and diabetes: pathogenesis and consequences. Br J Diabetes Vasc Dis 2011;11:230-234.
  • 37
    Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, Babiychuk EB. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94-102.
  • 38
    Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med 2012;172:1180-1182.
  • 39
    Asberg A, Hartmann A, Fjeldså E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 2001;1:382-386.
  • 40
    Lemahieu WP, Hermann M, Asberg A, Verbeke K, Holdaas H, Vanrenterghem Y, Maes BD. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005;5:2236-2243.
  • 41
    Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-571.